When i made the money i did on Acad people were saying the same thing. I sold Acad in the $15 range..Always someone like you who dont think it will happen. Its not for sure but its a GOOD chance.. Thats all..
Looking forward to it. Just picked up more for the coming run-up. Hope Amgen is right to
back-up this company. with their $25M non-refundable license fee and $10M in stock
purchase. A fast track by FDA on Omecarbil will make a lot of people happy.
First catalyst was a positive phase 3 trial. Second catalyst was the FDA telling them they needn't carry out their planned second phase 3 trial. They were told to present the NDA with the evidence from the one positive phase 3 trial .What has held down the stock price was ACAD saying they would be unable to present the NDA until late 2014. The FDA caught them off guard. They still need to do safety and drug interaction studies, and get their drug manufacturing lined up.